Molecular Partners Ownership
| MOLN Stock | USD 5.42 0.22 4.23% |
Shares in Circulation | First Issued 2013-03-31 | Previous Quarter 33.2 M | Current Value 33.2 M | Avarage Shares Outstanding 24.5 M | Quarterly Volatility 6.3 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Molecular |
Molecular Stock Ownership Analysis
The company has price-to-book ratio of 1.22. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Molecular Partners recorded a loss per share of 2.14. The entity had not issued any dividends in recent years. Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. The company was incorporated in 2004 and is headquartered in Schlieren, Switzerland. Molecular Partners operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 163 people. To find out more about Molecular Partners AG contact Patrick Amstutz at 41 44 755 77 00 or learn more at https://www.molecularpartners.com.Besides selling stocks to institutional investors, Molecular Partners also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Molecular Partners' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Molecular Partners' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Molecular Partners Quarterly Liabilities And Stockholders Equity |
|
Molecular Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Molecular Partners is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Molecular Partners AG backward and forwards among themselves. Molecular Partners' institutional investor refers to the entity that pools money to purchase Molecular Partners' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Bvf Inc | 2024-09-30 | 443.2 K | Suvretta Capital Management, Llc | 2024-06-30 | 400 K | Old Mission Capital Llc | 2024-06-30 | 10.4 K | Ubs Group Ag | 2024-06-30 | 3.5 K | Tang Capital Management Llc | 2024-06-30 | 2.5 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 734 | Rhumbline Advisers | 2024-06-30 | 269 | Qube Research & Technologies | 2024-06-30 | 16.0 | Royal Bank Of Canada | 2024-06-30 | 0.0 |
Molecular Partners Outstanding Bonds
Molecular Partners issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Molecular Partners uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Molecular bonds can be classified according to their maturity, which is the date when Molecular Partners AG has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| US60855RAL42 Corp BondUS60855RAL42 | View | |
| Molina Healthcare 4375 Corp BondUS60855RAJ95 | View | |
| US60855RAK68 Corp BondUS60855RAK68 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| International Game Technology Corp BondUS460599AD57 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View |
Molecular Partners Corporate Filings
6K | 31st of October 2024 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
F3 | 29th of October 2024 An amendment to the original Schedule 13D filing | ViewVerify |
| 25th of October 2024 Other Reports | ViewVerify | |
| 26th of June 2024 Other Reports | ViewVerify |
Pair Trading with Molecular Partners
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Molecular Partners position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Molecular Partners will appreciate offsetting losses from the drop in the long position's value.Moving against Molecular Stock
| 0.42 | GOSS | Gossamer Bio | PairCorr |
| 0.37 | VRDN | Viridian Therapeutics | PairCorr |
| 0.37 | TERN | Terns Pharmaceuticals | PairCorr |
| 0.35 | NTRB | Nutriband | PairCorr |
The ability to find closely correlated positions to Molecular Partners could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Molecular Partners when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Molecular Partners - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Molecular Partners AG to buy it.
The correlation of Molecular Partners is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Molecular Partners moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Molecular Partners moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Molecular Partners can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Molecular Partners AG. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Molecular Partners. If investors know Molecular will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Molecular Partners listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.14) | Revenue Per Share 0.182 | Quarterly Revenue Growth (0.73) | Return On Assets (0.21) | Return On Equity (0.37) |
The market value of Molecular Partners is measured differently than its book value, which is the value of Molecular that is recorded on the company's balance sheet. Investors also form their own opinion of Molecular Partners' value that differs from its market value or its book value, called intrinsic value, which is Molecular Partners' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Molecular Partners' market value can be influenced by many factors that don't directly affect Molecular Partners' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Molecular Partners' value and its price as these two are different measures arrived at by different means. Investors typically determine if Molecular Partners is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Molecular Partners' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.